- Home
- CWEN vs LNTH Comparison
CWEN vs LNTH Comparison
Compare CWEN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- LNTH
- Stock Information
- Founded
- CWEN 2012
- LNTH 1956
- Country
- CWEN United States
- LNTH United States
- Employees
- CWEN N/A
- LNTH N/A
- Industry
- CWEN Electric Utilities: Central
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CWEN Utilities
- LNTH Health Care
- Exchange
- CWEN Nasdaq
- LNTH Nasdaq
- Market Cap
- CWEN 3.8B
- LNTH 3.8B
- IPO Year
- CWEN 2013
- LNTH 2015
- Fundamental
- Price
- CWEN $35.58
- LNTH $56.76
- Analyst Decision
- CWEN Buy
- LNTH Buy
- Analyst Count
- CWEN 6
- LNTH 6
- Target Price
- CWEN $37.17
- LNTH $74.17
- AVG Volume (30 Days)
- CWEN 1.3M
- LNTH 1.3M
- Earning Date
- CWEN 11-04-2025
- LNTH 11-06-2025
- Dividend Yield
- CWEN 4.88%
- LNTH N/A
- EPS Growth
- CWEN 125.75
- LNTH N/A
- EPS
- CWEN 2.34
- LNTH 2.39
- Revenue
- CWEN $1,375,000,000.00
- LNTH $1,525,933,000.00
- Revenue This Year
- CWEN N/A
- LNTH N/A
- Revenue Next Year
- CWEN N/A
- LNTH $1.98
- P/E Ratio
- CWEN $15.17
- LNTH $23.33
- Revenue Growth
- CWEN 0.81
- LNTH 1.95
- 52 Week Low
- CWEN $24.40
- LNTH $47.25
- 52 Week High
- CWEN $36.89
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- CWEN 67.08
- LNTH 56.79
- Support Level
- CWEN $35.81
- LNTH $51.84
- Resistance Level
- CWEN $36.89
- LNTH $54.27
- Average True Range (ATR)
- CWEN 0.93
- LNTH 2.74
- MACD
- CWEN -0.01
- LNTH 0.09
- Stochastic Oscillator
- CWEN 71.62
- LNTH 55.21
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.